Compare DexCom, Inc. (DXCM) vs iShares Russell 2000 ETF (IWM) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

IWM trades at $295.49, up 0.35% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF has gained significant attention for outperforming large-cap benchmarks year-to-date, driven by renewed investor interest in small-cap stocks amid shifting interest rate expectations. Recent news highlights strong flows into small-cap ETFs, though some analysts caution about valuation traps and moderating growth.

Outlook remains positive given small-caps' historical performance during economic expansions, but risks include higher volatility, sensitivity to interest rates, and concentration concerns. The ETF's expense ratio of 0.19% is competitive, though slightly higher than some alternatives. Continued outperformance hinges on sustained economic growth and favorable monetary policy.